BioCryst Pharmaceuticals, Inc. (BCRX) key performance indicators and operating metrics (17 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| ORLADEYO Net Revenue | 148.35M | FY2026-Q1 |
| Non-GAAP Operating Profit | 54.24M | FY2026-Q1 |
| Other Revenues | 5.05M | FY2026-Q1 |
| Contribution margin | 80.00 percent | FY2025-Q4 |
| Senior credit facility (pro forma) | 400M | FY2025-Q4 |
| Non-GAAP Net Income | 35.6M | FY2025-Q3 |
| Royalty revenues paid and payable | 20M | FY2025-Q3 |
| Senior credit facility | 199M | FY2025-Q3 |
| Cash, cash equivalents, restricted cash & investments | 269M | FY2025-Q3 |
| Operating Profit (GAAP) | 29.6M | FY2025-Q3 |
| Launch-to-date OMERS royalties | 84M | FY2025-Q3 |
| Non-cash interest expense | 13M | FY2025-Q3 |
| Non-GAAP Operating Profit Excluding Stock-Based Compensation And Transaction-Related Costs | 51.7M | FY2025-Q3 |
| Royalty financing obligations - current | 34.31B | FY2025-Q1 |
Back to BCRX overview · BCRX earnings · BCRX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.